Table 2 |
|||
|
Frequency of HLA class II phenotypes |
|||
| HLA |
Controls |
Polymyositis |
Dermatomyositis |
|
|
|||
| n (%) |
n (%) |
n (%) |
|
|
|
|||
| DRB1 |
(n = 537) |
(n = 115) |
(n = 107) |
| 01 |
127 (23.6) |
25 (21.7) |
27 (25.2) |
| 02 |
145 (27.0) |
23 (20.0) |
19 (17.8) |
| 03 |
151 (28.1) |
72 (62.6) |
50 (46.7) |
| 04 |
195 (36.3) |
31 (27.0) |
39 (36.4) |
| 07 |
129 (24.0) |
11 (9.6) |
37 (34.6) |
| 08 |
37 (6.9) |
5 (4.3) |
2 (1.9) |
| 09 |
12 (2.2) |
1 (0.9) |
2 (1.9) |
| 10 |
8 (1.5) |
3 (2.6) |
0 (0) |
| 11 |
61 (11.4) |
16 (13.9) |
11 (10.3) |
| 12 |
11 (2.0) |
3 (2.6) |
1 (0.9) |
| 13 |
96 (17.9) |
18 (15.6) |
10 (9.3) |
| 14 |
30 (5.6) |
5 (4.3) |
5 (4.7) |
| p |
0.0001 |
0.009 |
|
| DQA1 |
(n = 142) |
(n = 110) |
(n = 104) |
| 01 |
92 (64.8) |
62 (56.4) |
57 (54.8) |
| 02 |
33 (23.2) |
10 (9.1) |
36 (34.6) |
| 03 |
60 (42.3) |
31 (28.2) |
39 (37.5) |
| 04 |
5 (3.5) |
3 (2.7) |
1 (1.0) |
| 05 |
55 (38.7) |
82 (74.5) |
58 (55.8) |
| 06 |
2 (1.4) |
2 (1.8) |
0 (0) |
| p |
0.0001 |
0.02 |
|
| DQB1 |
(n = 153) |
(n = 116) |
(n = 108) |
| 02 |
61 (39.9) |
76 (65.5) |
71 (65.7) |
| 03 |
87 (56.9) |
56 (48.3) |
57 (52.8) |
| 04 |
9 (5.9) |
5 (4.3) |
3 (2.8) |
| 05 |
42 (27.5) |
35 (30.2) |
32 (29.6) |
| 06 |
65 (42.5) |
37 (31.9) |
31 (28.7) |
| p |
0.02 |
0.008 |
|
|
|
|||
|
P, global probability for disease versus controls (using genotype data). n (%), number/percentage of patients with individual phenotypes. |
|||
|
Chinoy et al. Arthritis Research & Therapy 2006 8:R13 doi:10.1186/ar1862 |
|||
